Title: Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (The VQUIN MDR Trial): a protocol for a randomized controlled trial
Supplementary Appendix S2 6. Determine the incidence ratio of grade 3 or 4 adverse events in the active levofloxacin group, compared to the placebo control group.
7. Determine the ratio of death from any cause (except for violent or accidental causes) among the active levofloxacin group, compared to the placebo control group.
8. Evaluate the cost-effectiveness of 6 months of levofloxacin therapy, compared to placebo, in contacts of patients with MDR-TB, under programmatic conditions. 9. Determine the proportion of contacts with incident TB with acquired fluoroquinolone resistance in comparison to bacterial isolates of the index patient, in the levofloxacin group compared to the placebo group Additional objectives for the biomarker sub-study are to:
10. Determine the difference in specific biomarkers (including microRNAs) between treatment initiation and treatment completion for compliant participants allocated to levofloxacin compared to the placebo group;
11. Determine the difference in specific biomarkers (including microRNAs) for patients with microbiologically proven TB, compared with enrolled contacts with infection, and enrolled contacts that are uninfected.
Outcome definitions Bacteriologically confirmed tuberculosis
Bacteriologically-confirmed TB is defined as a positive identification of Mycobacterium tuberculosis by culture, GeneXpert MTB/RIF (Xpert) or another PCR-based diagnostic test in a contact with clinical or radiological evidence of disease.
A contact will be considered positive for bacteriologically-confirmed TB if: (a) at least one sample of sputum, or other body fluid or tissue is positive by culture, Xpert or another PCR-  AFB-positive alone on smear microscopy that is not culture or Xpert positive would be considered as supportive laboratory evidence.
 Probable EPTB will be based upon either additional investigations seeking microbiological confirmation (e.g. lymph node aspirate, CSF) or supportive clinical/radiological findings from laboratory investigation or imaging (e.g. pleural aspirate or ascitic tap, X-ray)  Any form of EPTB with supportive evidence (see above) that is not also bacteriologically confirmed would be considered as Clinically Probable TB.
Clinical TB should be classified as pulmonary, extra-pulmonary or both.
Possible clinical TB
Possible clinical TB is defined as known exposure to TB plus clinical or radiological evidence/abnormality that is not consistent with above definitions AND a decision was made to treat for TB. Possible clinical TB should be classified as pulmonary, extra-pulmonary or both. 
Latent tuberculosis infection (LTBI)
Known exposure to TB plus immunological evidence of infection with M. tuberculosis (TST/IGRA) plus no clinical or radiological evidence of disease
Definitions of incident TB in child contacts aged <15 years
It is important to have consistency in reporting of cases within studies and as far as possible between studies for purposes of valid comparison or possible future meta-analysis.
While the clinical, non-bacteriologically-confirmed definitions have uncertainty, it should be emphasized that they are being used to strengthen consistency of reporting, not as definitions to inform treatment decisions. They are for the purpose of classification of study endpoints.
Decisions to treat for TB (or not) will be made by a separate consensus panel on an individual patient basis. There are various factors that will influence treatment decisions that cannot be classified prospectivelyfor example, duration of symptoms, response of symptoms to other interventions, severity of illness (i.e. influencing urgency of referral and management), opportunity for follow-up and review prior to decision to treat, but that can be used retrospectively for classification purposes.
The previously suggested National Institutes of Health (NIH) case definitions were specifically designed for diagnostic assessment studies of intrathoracic TB in children and for where the entry point for the study would usually be children with symptoms suggestive of intrathoracic TB that presented to health services.
Note that in this MDR contact study, there are important differences to consider:
1. All children in this study will by definition already have "known exposure to TB". 3. Contact screening includes an active case-finding component that will identify children with TB at an earlier stage of disease than passive case-finding.
4. Some contact children may have extrapulmonary TB and so there is a need to include these in definitions.
5.
There are no data to inform what might constitute an "adequate treatment response" as supportive evidence in this context and so this feature will not be included. 
Bacteriologically confirmed TB in children

Probable clinical TB in children
Probable clinical TB is defined as known exposure to TB plus "well-defined" clinical evidence AND supportive radiological or laboratory evidence of pulmonary or extrapulmonary disease in a child who is not bacteriologically-confirmed.
The diagnosis of clinically probable TB is equivalent to the secondary outcome of "Clinical TB". The End Point Review Panel will reach a conclusion about the diagnosis of clinically probable TB on the basis of the following:
 Well-defined clinical evidence of clinically probable TB would include any TBrelated symptoms of over 14 days' duration that was not improving (e.g. cough, fever, night sweats, lethargy) or signs (e.g. documented failure to thrive i.e. flattening of  In children with no clinical evidence, radiological evidence to support pulmonary TB would only include marked parenchymal abnormality on CXR  AFB-positive alone on smear microscopy that is not culture or Xpert positive would be considered as supportive laboratory evidence.
 Probable EPTB will be based upon either additional investigations seeking microbiological confirmation (e.g. lymph node aspirate, CSF) or supportive clinical/radiological findings from laboratory investigation or imaging (e.g. pleural aspirate or ascitic tap, X-ray  Any form of EPTB with supportive evidence (see above) that is not also bacteriologically confirmed would be considered as Clinically Probable TB.
Probable clinical TB should be classified as either pulmonary, extrapulmonary or both.
Possible clinical TB in children
Possible TB is defined as known exposure to TB plus clinical or radiological evidence/abnormality that is not consistent with above definitions AND a decision is made to treat for TB. Possible clinical TB should be classified as pulmonary, extra-pulmonary or both.
Not TB
This is defined as known exposure to TB plus clinical symptoms or radiological features that resolve without treatment for TB 
Drug toxicity
Drug toxicity will be evaluated during an interview with contacts once each month during treatment.
Death
The secondary mortality outcome will be death from any cause except for violent (e.g. homicide) or accidental (e.g. motor vehicle accident) causes.
Details of the death will be obtained from health service medical records, family members or other official sources (including death certificates). Additional details of the circumstances surrounding the death will be collected to enable the IDMC to evaluate whether the death was likely attributable to the study medication.
A TB death is a death where TB is considered by the IDMC to be the most likely or major contributing cause of death. Supplementary Appendix S10 A non-TB death is a death where factors other than TB is considered the most likely or major contributing cause of death.
Drug discontinuation owing to adverse drug reaction
Subjects will be deemed to have discontinued owing to an adverse drug reaction if the drug is ceased after recurring grade 3 or grade 4 toxicity.
For any recurring grade 3 or grade 4 toxicity, the study drug will be temporarily withheld, and may be permanently discontinued in the affected individual at the discretion of the Expert Clinical Panel.
Drug discontinuation to causes other than adverse drug reactions
Causes of drug discontinuation not related to adverse drug reactions may include loss to followup, withdrawal from the study or not taking study therapy for at least 3 months. In such circumstances, the Principal Investigator may decide it is no longer advisable to continue the study drugs.
Completion of six months of therapy
A contact will be defined to have completed the study therapy if they complete 80% or more of the total prescribed doses within a total period of 30 weeks after randomization.
Adherence
Adherence will be assessed at the end of each month of treatment with pill counts. Standardized questionnaires will also be used to assess compliance. Contacts will be considered non- 
Proportion of contacts successfully treated
Contacts will be classified as successfully treated if they either achieve outcomes of (a) treatment success, or (b) cure according to WHO treatment definitions (1).
Procedures for follow-up of contacts treated for TB disease
All contacts treated for co-prevalent TB, and randomized contacts treated for incident TB, will have the following follow-up performed.
Co-prevalent disease is defined as TB that is present at the time of enrolment, based upon diagnostic tests performed at the baseline. Contacts with co-prevalent TB will have samples collected and stored, for subsequent comparison with other contacts in their household who develop incident disease.
Contacts in which tuberculosis is to be suspected
Symptoms that will be considered to indicate suspected TB, either at the time of baseline Supplementary Appendix S12 assessment or at any time during follow-up are listed in Table S1 . be considered as suspects) then they will be reassessed again when 2 weeks has passed since symptom onset, to determine whether the cough is persistent. If the symptoms have resolved at the time of the second assessment, then no additional sputum testing will be required and the contact will not be considered a suspect on account of the cough. If the cough has persisted for a total of more than 2 weeks in total then they will be investigated as a suspect (including additional sputum testing as described below). **Children with ANY symptom (cough or fever) defined in the above table should be followed until symptom resolutionwith follow-up after 1-2 weeks if symptoms do not meet duration criteria specified above. Persistent cough or prolonged fever not responding to treatment for the most likely alternative cause requires TB investigation. 
